STAT3 and non-small cell lung carcinoma: In the present study, we demonstrated for the first time that ITGA5 promoted gefitinib resistance in NSCLC via STAT3/CXCL1 axis in an EGFR-independent manner, broadening the understanding of gefitinib resistance in NSCLC.